These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1121 related items for PubMed ID: 25515492

  • 1. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
    Yang X, Iyer AK, Singh A, Milane L, Choy E, Hornicek FJ, Amiji MM, Duan Z.
    Pharm Res; 2015 Jun; 32(6):2097-109. PubMed ID: 25515492
    [Abstract] [Full Text] [Related]

  • 2. MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer.
    Yang X, Iyer AK, Singh A, Choy E, Hornicek FJ, Amiji MM, Duan Z.
    Sci Rep; 2015 Feb 17; 5():8509. PubMed ID: 25687880
    [Abstract] [Full Text] [Related]

  • 3. Cosilencing of PKM-2 and MDR-1 Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian Cancer.
    Talekar M, Ouyang Q, Goldberg MS, Amiji MM.
    Mol Cancer Ther; 2015 Jul 17; 14(7):1521-31. PubMed ID: 25964202
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance.
    Yhee JY, Song S, Lee SJ, Park SG, Kim KS, Kim MG, Son S, Koo H, Kwon IC, Jeong JH, Jeong SY, Kim SH, Kim K.
    J Control Release; 2015 Jan 28; 198():1-9. PubMed ID: 25481438
    [Abstract] [Full Text] [Related]

  • 7. Downregulation of gene MDR1 by shRNA to reverse multidrug-resistance of ovarian cancer A2780 cells.
    Zhang H, Wang J, Cai K, Jiang L, Zhou D, Yang C, Chen J, Chen D, Dou J.
    J Cancer Res Ther; 2012 Jan 28; 8(2):226-31. PubMed ID: 22842366
    [Abstract] [Full Text] [Related]

  • 8. Delivery of MTH1 inhibitor (TH287) and MDR1 siRNA via hyaluronic acid-based mesoporous silica nanoparticles for oral cancers treatment.
    Shi XL, Li Y, Zhao LM, Su LW, Ding G.
    Colloids Surf B Biointerfaces; 2019 Jan 01; 173():599-606. PubMed ID: 30352381
    [Abstract] [Full Text] [Related]

  • 9. Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors.
    Ganesh S, Iyer AK, Morrissey DV, Amiji MM.
    Biomaterials; 2013 Apr 01; 34(13):3489-502. PubMed ID: 23410679
    [Abstract] [Full Text] [Related]

  • 10. Hyaluronic acid-decorated PLGA-PEG nanoparticles for targeted delivery of SN-38 to ovarian cancer.
    Vangara KK, Liu JL, Palakurthi S.
    Anticancer Res; 2013 Jun 01; 33(6):2425-34. PubMed ID: 23749891
    [Abstract] [Full Text] [Related]

  • 11. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
    Li TS, Yawata T, Honke K.
    Eur J Pharm Sci; 2014 Feb 14; 52():48-61. PubMed ID: 24178005
    [Abstract] [Full Text] [Related]

  • 12. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
    Zhong Y, Zhang J, Cheng R, Deng C, Meng F, Xie F, Zhong Z.
    J Control Release; 2015 May 10; 205():144-54. PubMed ID: 25596560
    [Abstract] [Full Text] [Related]

  • 13. Co-Delivery of Curcumin and Paclitaxel by "Core-Shell" Targeting Amphiphilic Copolymer to Reverse Resistance in the Treatment of Ovarian Cancer.
    Zhao MD, Li JQ, Chen FY, Dong W, Wen LJ, Fei WD, Zhang X, Yang PL, Zhang XM, Zheng CH.
    Int J Nanomedicine; 2019 May 10; 14():9453-9467. PubMed ID: 31819443
    [Abstract] [Full Text] [Related]

  • 14. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
    Wu Y, Zhang Y, Zhang W, Sun C, Wu J, Tang J.
    Colloids Surf B Biointerfaces; 2016 Feb 01; 138():60-9. PubMed ID: 26655793
    [Abstract] [Full Text] [Related]

  • 15. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer.
    Wen ZM, Jie J, Zhang Y, Liu H, Peng LP.
    Biochem Biophys Res Commun; 2017 Dec 02; 493(4):1430-1437. PubMed ID: 28958938
    [Abstract] [Full Text] [Related]

  • 16. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
    Kim GH, Won JE, Byeon Y, Kim MG, Wi TI, Lee JM, Park YY, Lee JW, Kang TH, Jung ID, Shin BC, Ahn HJ, Lee YJ, Sood AK, Han HD, Park YM.
    Drug Deliv; 2018 Nov 02; 25(1):1394-1402. PubMed ID: 29890852
    [Abstract] [Full Text] [Related]

  • 17. PEGylated hyaluronic acid-modified liposomal delivery system with anti-γ-glutamylcyclotransferase siRNA for drug-resistant MCF-7 breast cancer therapy.
    Ran R, Liu Y, Gao H, Kuang Q, Zhang Q, Tang J, Fu H, Zhang Z, He Q.
    J Pharm Sci; 2015 Feb 02; 104(2):476-84. PubMed ID: 25256603
    [Abstract] [Full Text] [Related]

  • 18. NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo.
    Yang X, Feng Y, Gao Y, Shen J, Choy E, Cote G, Harmon D, Zhang Z, Mankin H, Hornicek FJ, Duan Z.
    Gynecol Oncol; 2015 Apr 02; 137(1):134-42. PubMed ID: 25677062
    [Abstract] [Full Text] [Related]

  • 19. Ovarian cancer targeted hyaluronic acid-based nanoparticle system for paclitaxel delivery to overcome drug resistance.
    Wang L, Jia E.
    Drug Deliv; 2016 Jun 02; 23(5):1810-7. PubMed ID: 26530693
    [Abstract] [Full Text] [Related]

  • 20. Folate and CD44 receptors dual-targeting hydrophobized hyaluronic acid paclitaxel-loaded polymeric micelles for overcoming multidrug resistance and improving tumor distribution.
    Liu Y, Sun J, Lian H, Cao W, Wang Y, He Z.
    J Pharm Sci; 2014 May 02; 103(5):1538-47. PubMed ID: 24619562
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.